Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0025202 (melanoma)
 69,561 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Organ distribution and blood concentration profiles were compared following injection of mice with radiolabeled test agents via the lateral tail vein or retroorbital venous sinus. Monoclonal antibodies directed against B16 melanoma of C57BL/6 origin were labeled with iodine-125. Thymocytes from BALB/c mice and B16 melanoma cells were labeled with technetium-99m sodium pertechnetate (Na 99mTcO4). Animals were injected with 5 microCI of iodinated antibody, 5 X 10(5) syngeneic thymocytes, 2.5 X 10(5) melanoma cells, or 10 microCi Na 99mTcO4 in 0.2 ml saline via either route. In non-tumor-bearing C57BL/6 mice radiolabeled monoclonal antibody was found primarily in the gastrointestinal tract, liver, and blood. Na 99mTcO4 localized in the gastrointestinal tract, 99mTc-labeled thymocytes in the spleen and liver, and 99mTc-labeled B16 melanoma cells in the liver and lungs. Pharmacokinetic analysis of blood samples taken 4, 8, and 12 min following injection of the labeled agents suggested that the iodinated antibody had less vascular permeability than Na 99mTcO4 and that thymocytes and B16 melanoma cells were trapped in the pulmonary vasculature as they passed through the lungs. It is noteworthy that no biologically significant differences in organ distribution patterns or blood decay profiles were found between lateral tail vein and retroorbital routes. The data clearly indicate that these routes can be used interchangeably with one another for intravenous injections.
 ...
PMID:Injection of cells and monoclonal antibodies into mice: comparison of tail vein and retroorbital routes. 609 Nov 49

Various aspects of radiotherapeutic techniques used in treating ocular tumors are discussed. Previous and current "standard" modalities are briefly reviewed, including beta and gamma emitters, 60Co, 125I, and charged particles. In particular, emphasis is placed upon techniques under development that use biomolecules to physiologically target radioactive or stable isotopes to ocular melanoma. These procedures include 35S-thiouracil, 127I-deoxyuridine in conjunction with irradiation with photons from 145Sm, neutron capture therapy, and various combinations of the above. Thiouracil shows particular promise because of its incorporation during malanin synthesis in growing melanoma. Radiosensitization and stimulation of Auger cascades via introduction of iodine in DNA followed by irradiation with activating photons of appropriate energy (from 145Sm) has been shown to be effective in vitro. Various molecules may be used to transport boron to ocular melanoma, including thiouracil, thus allowing selective irradiation of tumor cells via 10B (n, alpha) 7Li reaction.
 ...
PMID:New radiotherapeutic techniques in nuclear ophthalmology. 632 76

When compared with Cobalt-60, the physical properties of Iodine-125 make it an attractive alternative therapy for consideration in the management of selected choroidal melanomas. The low-energy gamma emission can be nearly completely shielded by a thin sheet of gold 0.4 mm thick. Iodine-125 contained in a gold-backed episcleral plaque may reduce radiation exposure to non-target tissues of the eye including the optic nerve and macula. Iodine-125 is readily available, is adaptable to specific tumour locations and size, and offers very little radiation hazard to handlers. The physical characteristics of Iodine-125 are suitable for treatment of relatively large ocular tumours. Preliminary experience at the Mayo Clinic with Iodine-125 in the management of 12 patients with malignant melanoma to the choroid who have been followed between six months and two and a quarter years, indicate the effectiveness of Iodine-125 in promoting tumour shrinkage. In 11 of the 12 treated eyes, there is evidence of decreased tumour thickness as judged by ultrasonography and photography.
 ...
PMID:Preliminary observations regarding the use of iodine-125 in the management of choroidal melanoma. 658 67

We have studied the behaviour of 125I-labelled alpha-MSH under different experimental conditions. Until now, the chloramine T method had been used by most investigators with variable results. We have tested three other labelling techniques based on 125I mild oxidation: (1) an enzymatic method with lactoperoxidase, (2) a sparingly soluble chloramine method (T.D.G.U.) and (3) modified chloramine T procedure, 'the iodine volatilization method'. Labelled hormone obtained after each kind of iodination was assayed for immunoreactivity. In addition, time course degradation was measured by classical RIA incubation procedures. Charcoal-dextran was used to separate bound and free antigen. We have found chloramine T-iodinated alpha-MSH to be significantly more damaged than preparations obtained by other methods and to be less stable when stored at -18 degrees C. No differences were found between the differently labelled 125I-labelled alpha-MSH fresh preparations in binding to surface receptors of human melanoma cell lines in culture.
 ...
PMID:Comparison and evaluation of different methods for alpha-MSH labelling. 675 23

The production of highly purified, chemically well defined, iodinated beta-melanotropin possessing full biological activity is described. beta-Melanotropin, purified by high pressure liquid chromatography, was iodinated using Iodogen as the oxidizing agent. Biological activity was recovered, following iodination, by incubating the iodinated peptide mixture in 0.75 M dithiothreitol at 37 degrees C for 18-24 h. The qualitative and quantitative effects of dithiothreitol and the changes that occurred in the iodination mixture with time were examined using high pressure liquid chromatography. This separation technique has proved to be a useful tool both for optimizing the iodination procedure and for the rapid, efficient purification of mono- and diiodinated beta-melanotropins. Amino acid analysis of these two peptides revealed modifications only of the one tyrosine residue (Tyr 5): the expected incorporation of iodine to form mono- or diiodo tyrosine. Monoiodo-beta-melanotropin had full biological activity, as measured by tyrosinase stimulation in Cloudman S91 melanoma cells, while diiodo-beta-melanotropin was an order of magnitude less active.
 ...
PMID:Iodination of beta-melanotropin. Time course analysis of reaction mixtures by high pressure liquid chromatography and characterization of biologically active mono- and diiodo-beta-melanotropin. 680 93

Cloudman (S91) murine melanoma cells were treated with 4'-hydroxymethyltrioxsalen (HMT), a bifunctional psoralen and exposed to long-wavelength (365 nm) ultraviolet light. DNA content of the cells stained with propidium iodide was measured by flow cytometry, and cell cycle phases were delineated from the DNA histograms by using a curve-fitting routine. We found that HMT in combination with long-wavelength (365 nm) ultraviolet irradiation blocked melanoma cells in different phases of the cell cycle, depending on the dose of long-wavelength (365 nm) ultraviolet light and the concentration of HMT. The binding of [3H]HMT to DNA was measured parallel with cell cycle analyses. Treatments with HMT at concentrations corresponding to about 1 HMT bound per 10(6) base pairs of DNA led to the accumulation of cells with predominantly G2 DNA content. At higher concentrations (2 to 3 HMT/10(6) base pairs), the cells were blocked in the S and G1 phases. In conclusion, we have shown that extremely sparse substitution of HMT to DNA blocks melanoma cells in the G2 phase or other phases of the cell cycle in a dose-dependent manner.
 ...
PMID:Dose-related effects of psoralen and ultraviolet light on the cell cycle of murine melanoma cells. 707 3

We have shown that thioamides are incorporated as false precursors into melanin during its synthesis. To be clinically useful in the diagnosis or therapy of melanotic melanomas, they would have to be tagged with an appropriate isotope or possibly a cytotoxic moiety. 125I-Thiouracil (125I-TU) is here shown to be accumulated in the melanin of melanotic melanomas transplanted into mice in a similar way as is 14C-thiouracil (14C-TU). 125I-TU gives tumour/liver and tumour/muscle ratios up to 22 and 778 respectively, at 4 days after administration. 125I-TU is accumulated by melanoma cells in vitro more effectively than 14C-TU (125I-TU/14C-TU, 2.7), while the in vivo accumulation into melanomas is slightly lower for 125I-TU as compared to 14C-TU (125I-TU/14C-TU, 0.35). This appears to be due to a partial deiodination (less than 14% of the dose within 4 days) and probably a more rapid excretion of 125I-TU or its metabolite(s). The accumulation of radioactivity in the thyroid can essentially be eliminated by pretreatment with potassium iodide and/or thyroxine. 125I-Propylthiouracil is also accumulated in melanotic melanoma cells in vivo and in vitro, but at a lower level than in 125I-TU and 14C-TU.
 ...
PMID:Accumulation of 125I-labelled thiouracil and propylthiouracil in murine melanotic melanomas. 713 63

The attachment of cells to plastic tissue culture plates is a widely used criterion of cell viability in microcytotoxicity assays. When cell suspensions of primary human colon carcinoma and melanoma cells which were of low initial viability (assessed by trypan blue exclusion) were allowed to adhere to tissue culture plates, many of the adhering cells did not satisfy other criteria of cell viability. They did not stain with fluorescein diacetate but did stain with propidium iodide and fluorescein-labelled antinuclear antibodies. Using complement-mediated cytotoxicity, relatively weak activity was inconsistently demonstrated against these cells. On the other hand, strong activity was always demonstrated against highly viable cells from one colon carcinoma and two melanoma cell lines. Immunologically mediated damage to these cells was demonstrated readily by loss of the ability to stain with fluorescein diacetate, but not by cell detachment.
 ...
PMID:Criteria of cell killing in vitro. 726 20

The low-energy radioactive source iodine-125 is ideal for the irradiation of an intraocular tumor tumor such as a choroidal melanoma. The energy (28 kev) of iodine-125 should be sufficient to allow sterilization of tumors as high as 10 mm. However, shielding of 18-kev photons can be achieved with thin metal (eg, gold) plaques. Thse eye plaques can be individually designed for each eye tumor, depending on its size, shape, and location. This paper deals with the basic considerations and preliminary observations that have lead us to the adoption of iodine-125 as the sole source for the radiation treatment of all intraocular tumors.
 ...
PMID:Radiotherapy of choroidal melanoma with iodine-125. 741 47

Radioactive iodine 125 is a low-energy gamma isotope with physical characteristics suitable for irradiation of intraocular tumors. Metal ophthalmic applicators have been designed to shield vital ocular structures while allowing irradiation of the tumor. We compared the radiation effects of iodine 125 and cobalt 60. The Greene melanoma was transplanted into the suprachoroidal space of rabbits. The tumor then grew as an intraocular mass, was irradiated, and was followed up for two months before enucleation. Histopathologic examination defined the extent of the radiation damage to the tumor and other ocular structures from the iodine 125 and from the cobalt 60. The eye irradiated with iodine 125 suffered minimal radiation damage, whereas the tumor was sterilized. The eye irradiated with cobalt 60 showed substantial radiation damage, and the melanoma was incompletely treated. Our results support the use of iodine 125 in treating intraocular tumors. More research is needed as to optimum total dose and dose rate.
 ...
PMID:Irradiation of choroidal melanoma with iodine 125 ophthalmic plaque. 741 84


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>